Tipiracil 6.14 MG / trifluridine 15 MG Oral Tablet — RxCUI 1670311
RxNorm drug concept · Semantic clinical drug
RxCUI 1670311
Semantic clinical drug · SCD
● Current RxNorm concept 2 FDA products
6 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1670311
Official nameTipiracil 6.14 MG / trifluridine 15 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped2
Package NDCs mapped6
Reported Medicaid activity (SDUD)1,725 prescriptions · 16 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Trifluridine and Tipiracil: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Lonsurf is a chemotherapy medication used when colorectal cancer or stomach/esophageal junction cancer has spread and other treatments have already been tried. It's not a first-lin...
- What exactly is Lonsurf treating, and why am I on it?
- Not every single day — Lonsurf follows a cycle. You take it twice a day with food for 5 days in a row, take 2 days off, then take it again for another 5 days, then you get about 2...
- How do I take this medication — do I take it every day?
🕸️ Concept Web — How Tipiracil 6.14 MG / trifluridine 15 MG Oral Tabl... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Tipiracil 6.14 MG / trifluridine 15 MG Oral Tablet
RxCUI 1670311 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 3
The active substance itself — no strength, form, or brand attached yet.
-
Tipiracil
1670304IN -
Trifluridine
10803IN -
Tipiracil / trifluridine
1670310MIN
-
Tipiracil
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Lonsurf
1670317BN
-
Lonsurf
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Tipiracil / trifluridine Oral Tablet
1670309SCDF -
Tipiracil / trifluridine Oral Product
1670307SCDG -
Tipiracil / trifluridine Pill
1670308SCDG -
Tipiracil / trifluridine Oral Tablet [Lonsurf]
1670319SBDF -
Lonsurf Oral Product
1670320SBDG -
Lonsurf Pill
1670321SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Tipiracil / trifluridine Oral Tablet
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Tipiracil 6.14 MG
1670305SCDC -
Trifluridine 15 MG
1670306SCDC -
Tipiracil 6.14 MG / trifluridine 15 MG Oral Tablet [Lonsurf]
1670322SBD -
Tipiracil 6.14 MG / trifluridine 15 MG [Lonsurf]
1670318SBDC
-
Tipiracil 6.14 MG
Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Tipiracil 6.14 MG
SCDC · 1670305 -
Trifluridine 15 MG
SCDC · 1670306 -
Tipiracil / trifluridine Oral Tablet
SCDF · 1670309 -
Tipiracil / trifluridine Oral Product
SCDG · 1670307 -
Tipiracil / trifluridine Pill
SCDG · 1670308
Brand-Name Concepts
-
Tipiracil 6.14 MG / trifluridine 15 MG Oral Tablet [Lonsurf]
SBD · 1670322 -
Tipiracil 6.14 MG / trifluridine 15 MG [Lonsurf]
SBDC · 1670318 -
Tipiracil / trifluridine Oral Tablet [Lonsurf]
SBDF · 1670319 -
Lonsurf Oral Product
SBDG · 1670320 -
Lonsurf Pill
SBDG · 1670321 -
Lonsurf
BN · 1670317
📦 FDA Products & Package NDCs
2 products · 6 package NDCs
6 package NDCs map to RxCUI 1670311 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 64842-1020-01 | 20 TABLET, FILM COATED in 1 BOTTLE (64842-1020-1) | LONSURF | Taiho Pharmaceutical Co., Ltd. | 2015-10-07 |
| 64842-1020-02 | 40 TABLET, FILM COATED in 1 BOTTLE (64842-1020-2) | LONSURF | Taiho Pharmaceutical Co., Ltd. | 2015-11-11 |
| 64842-1020-03 | 60 TABLET, FILM COATED in 1 BOTTLE (64842-1020-3) | LONSURF | Taiho Pharmaceutical Co., Ltd. | 2015-10-21 |
| 64842-1025-01 | 20 TABLET, FILM COATED in 1 BOTTLE (64842-1025-1) | LONSURF | Taiho Pharmaceutical Co., Ltd. | 2015-10-07 |
| 64842-1025-02 | 40 TABLET, FILM COATED in 1 BOTTLE (64842-1025-2) | LONSURF | Taiho Pharmaceutical Co., Ltd. | 2015-11-11 |
| 64842-1025-03 | 60 TABLET, FILM COATED in 1 BOTTLE (64842-1025-3) | LONSURF | Taiho Pharmaceutical Co., Ltd. | 2015-10-21 |
Observed labelers:
Taiho Pharmaceutical Co., Ltd. (6)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.